Table 3.

Oral cancer medications prescribed, n=274 at baseline, n=236 at 8 weeks

Oral cancer medications	Baseline, n (%)	8 weeks, n (%)
Cytotoxics*	95 (35)	81 (34)
Kinase inhibitors†	129 (47)	110 (47)
Sex hormone inhibitors‡	27 (10)	26 (11)
Other: IMIDs, PARP inhibitors, and mTOR inhibitors§	23 (8)	19 (8)

*Cytotoxics included capecitabine, temozolomide, tipiracil, trifluridine, ^†Kinase inhibitors included crizotinib, erlotinib, gefitinib, imatinib, lapatinib, pazopanib, regorafenib, sorafenib, sunitinib, ^‡Sex hormones included enzalutamide, letrozolec and abiraterone acetate, ^§Other category: Everolimus, olaparib, vorinostat. PARP: Ribose polymerase, IMIDs: Immunomodulatory drugs, mTOR: Mammalian target of rapamycin